Christopher J Morabito
Chief Tech/Sci/R&D Officer at ASTRIA THERAPEUTICS, INC.
Net worth: - $ as of 29/04/2024
Christopher J Morabito active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ASTRIA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 14/07/2022 | - |
Career history of Christopher J Morabito
Former positions of Christopher J Morabito
| Companies | Position | Start | End |
|---|---|---|---|
| FULCRUM THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 09/05/2021 | 12/07/2022 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Chief Tech/Sci/R&D Officer | 30/09/2016 | 30/06/2020 |
| MERCK & CO., INC. | Director/Board Member | 30/09/2010 | 31/03/2014 |
Cardurion Pharmaceuticals LLC
 Cardurion Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardurion Pharmaceuticals LLC is a cardiovascular biotechnology company, which engages in the development of therapeutics for the treatment of heart failure and cardiovascular diseases. The company was founded by Michael E. Mendelsohn in 2017 and is headquartered in Boston, MA. | Chief Tech/Sci/R&D Officer | - | - |
Training of Christopher J Morabito
| Franklin & Marshall College | Undergraduate Degree |
| Penn State Hershey College of Medicine | Doctorate Degree |
Statistics
International
| United States | 7 |
| Japan | 2 |
Operational
| Chief Tech/Sci/R&D Officer | 4 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| ASTRIA THERAPEUTICS, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Private companies | 1 |
|---|---|
Cardurion Pharmaceuticals LLC
Cardurion Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cardurion Pharmaceuticals LLC is a cardiovascular biotechnology company, which engages in the development of therapeutics for the treatment of heart failure and cardiovascular diseases. The company was founded by Michael E. Mendelsohn in 2017 and is headquartered in Boston, MA. | Health Technology |
